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Abstract 
Cerebral involvement frequently occurs in association with progression or relapse of 
malignant lymphoma. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and 
prednisolone, the standard chemotherapy for malignant lymphoma, is an ineffective 
treatment for cerebral involvement because these drugs cannot cross the blood-brain 
barrier. Therefore, various alternative strategies have been attempted. Although high-dose 
methotrexate combined with whole-brain radiotherapy is widely used to treat primary 
central nervous system lymphoma, there is no standard therapy to treat cerebral 
involvement in malignant lymphoma. Furthermore, high-dose methotrexate in combination 
with whole-brain radiotherapy is not always effective, and high rates of neurotoxicity are 
often observed, particularly in the elderly. To expand the therapeutic options for central 
nervous system involvement in recent years, systemic chemotherapies, including rituximab, 
high-dose methotrexate, and other agents that act during the S, G2, and M phases of the cell 
cycle, have been attempted. In our hospital, cladribine, a purine analogue with a cytocidal 
effect on resting malignant cells (G0/G1 phase of the cell cycle), has been used in 
combination with rituximab, which exhibits antitumor effects on nodal and extranodal 
lesions of relapsed and/or refractory B cell lymphomas, particularly cerebral lesions. Here, 
we report 2 representative cases of patients who were treated with cladribine plus rituximab 
and survived for 30 months (died of sepsis) and 52 months (still alive), respectively. The  
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outcomes of these cases suggest that cladribine plus rituximab combination therapy with 
whole-brain radiotherapy may be very useful as salvage therapy for secondary central 
nervous system lymphoma and as initial therapy for primary central nervous system 
lymphoma. 
 
Introduction 
Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) therapy is an 
effective systemic chemotherapy for non-Hodgkin’s lymphoma, and CHOP-based 
regimens have been widely used. However, most of these drugs cannot cross the blood-
brain barrier, and thus they fail to attain effective concentrations in the brain. Indeed, 
many researchers have reported that CHOP therapy is not very effective for primary 
central nervous system lymphoma (CNSL) or malignant lymphoma with cerebral or 
meningeal involvement. 
Various other therapeutic strategies for primary CNSL have been attempted. Of note, 
systemic high-dose methotrexate (MTX; ≥3 g/m2) combined with whole-brain 
radiotherapy (WBRT; 30–45 Gy) was shown to be very effective in prolonging survival 
time, and still plays a central role in the treatment of primary CNSL. However, this 
therapy is associated with serious side effects, including renal dysfunction, hepatic 
dysfunction, interstitial pneumonia, and myelosuppression, as well as 
leukoencephalopathy in elderly patients. A new therapeutic option for both nodal and 
extranodal lesions is rituximab, a chimeric monoclonal antibody against the CD20 
antigen. Rituximab alone has limited efficacy, but in combination with other drugs (e.g. 
temozolomide) its usefulness after progression or relapse of primary CNSL has been 
suggested. 
In our department, rituximab plus cladribine (RC) combination therapy has been 
used for relapsed and/or refractory B cell lymphomas. Cladribine (2-chloro-2-
deoxyadenosine) is a purine analogue with a very potent inhibitory effect on the 
proliferation of lymphoma. In cells, cladribine is phosphorylated to the 
pharmacologically active form 2-CdATP, and then incorporated into the DNA chain of 
both proliferating and resting cells, which causes cell death. The presence of 2-CdA-
metabolizing enzyme (adenosine deaminase) in lymphocytes and monocytes impedes 
the increase in the intracellular concentration of active 2-CdATP. By substituting 
chlorine for hydrogen in deoxyadenosine, cladribine is protected from enzymatic 
degradation. 
Treatment of relapsed or refractory non-Hodgkin’s lymphoma, unsuccessfully 
treated with CHOP therapy, will need to be effective for both nodal and extranodal 
lesions and to have no cross-resistance to CHOP therapy. RC combination therapy 
fulfills these requirements. In this article, we report 2 cases of malignant B-cell 
lymphoma with cerebral involvement responsive to RC combination therapy.  
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Case Presentations 
Case 1 
High lactate dehydrogenase was found in a 76-year-old man by a neighborhood physician at the 
end of 1999; however, the cause was not investigated. In March 2003, the patient visited our 
department with a chief complaint of general malaise. Abdominal CT revealed splenomegaly, and 
acute exacerbation of indolent malignant lymphoma was suspected. In April 2003, he was admitted to 
our department for close examination and treatment. Although no superficial lymph node swelling 
was found upon admission, whole-body CT revealed some enlargement of the submandibular-cervical 
and mediastinal lymph nodes, and 67Ga scintigraphy revealed intense 67Ga uptake by the spleen. 
Furthermore, a stomach biopsy specimen contained malignant lymphoma cells (CD20+ B cells), and 
the bone marrow aspirate contained abnormal lymphocytes.  
Also in April 2003, the patient underwent total gastrectomy, splenectomy, and cholecystectomy, 
and was diagnosed with stage IV intravascular large B-cell lymphoma (CD5–, CD10–, CD20+,  
CD45RO–, bcl2+, bcl6–, EBER(ISH)–). After 4 cycles of rituximab, pirarubicin, cyclophosphamide, 
vincristine, and prednisolone (R-THP-COP) therapy, the nodal lesions were generally reduced, which 
led to the patient’s discharge in July 2003. He was given 2 additional cycles of R-THP-COP; however, in 
September 2003, he required rehospitalization after a brain CT revealed many central nervous system 
lesions. High-dose MTX combined with WBRT (total dose of 36 Gy) was immediately administered, 
but in vain. Given his advanced age and weakness, high-dose cytosine arabinoside therapy was not 
considered. Instead, he received 2 cycles of RC combination therapy (375 mg/m2 rituximab 
intravenously on day 1 and 0.1 mg/kg cladribine intravenously once a day on days 2–6), and most of 
his intracranial lesions disappeared by November 2003. He was ambulatory on discharge and had no 
neurological symptoms. He completed another 4 cycles of RC combination therapy by April 2004 (fig. 
1), and complete response (Response Evaluation Criteria in Solid Tumors (RECIST) classification) was 
maintained until March 2006. After 6 cycles of RC combination therapy, pancytopenia was observed 
in May 2004. Chemotherapy-related myelodysplastic syndrome (MDS) was suspected by laboratory 
examination, including bone marrow aspiration. In January 2006, he developed a high fever and was 
urgently admitted to our department where he was treated for recurrent Gram-positive and Gram-
negative sepsis. In March 2006, he was transferred to another hospital for hospice care because he 
wished no further aggressive treatment. No neurotoxicity due to chemotherapy and WBRT was 
observed during the entire course of treatment. 
Case 2 
A 64-year-old man consulted a neighborhood physician in January 2008 because of memory loss 
and disorientation, which had become severe at the end of 2007. Brain MRI revealed a neoplastic 
lesion in the left splenium of the corpus callosum and in the medial side of the trigone of the left 
lateral ventricle and an extensive perilesional high-intensity area that appeared to be white matter 
edema (fig. 2). At the end of January 2008, he was admitted to our department for close examination 
and treatment. 
Splenic lymphoma with villous lymphocytes with central nervous system involvement and bone 
marrow invasion by malignant lymphoma cells (B cell, CD20+) was diagnosed based on whole-body 
CT, brain MRI, lumbar puncture, and bone marrow aspiration. RC combination therapy with WBRT 
(40 Gy) was started, and his clinical symptoms immediately decreased after 1 cycle (before the end of 
WBRT). High-dose MTX therapy was not utilized because the lymphoma cells had spread to various 
tissues, including the brain, and an adequate effect could not be expected with MTX therapy alone. 
In June 2008, after 4 cycles (1 cycle every 4 weeks) of RC combination therapy, the intracranial 
lesion was markedly reduced, and the surrounding white matter edema improved (fig. 2). The 
treatment response was considered a complete response, and this status has been maintained for 
more than 52 months. To avoid myelosuppression, RC combination therapy was finished in 4 cycles. 
However, the patient unfortunately developed leukoencephalopathy in January 2010.  
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Discussion 
Primary CNSL is a rare type of brain tumor and a rare form of malignant lymphoma. 
However, cerebral involvement frequently occurs in association with progression or 
relapse of malignant lymphoma. CHOP therapy, the standard chemotherapy for 
malignant lymphoma, is an inefficient treatment for cerebral involvement because of 
the blood-brain barrier. Therefore, various alternative strategies have been attempted. 
Since surgical removal of CNSL alone results in a mean survival of 1–2 months [1], it is 
not performed in patients with an established diagnosis of malignant lymphoma. In 
addition, steroids are known to reduce CNSL, but usually only for a few months. Until 
recently, WBRT played a central role in the treatment of primary CNSL. However, 
Nelson et al. [2] reported a relapse rate of over 80% within the whole-brain irradiation 
field and boost irradiation field. In addition, the 5-year survival rate was as low as 7% 
[3, 4], indicating that primary CNSL may be difficult to control with WBRT alone. The 
results of many subsequent studies have led to the adoption of high-dose MTX 
combined with WBRT as a current mainstay of primary CNSL treatment. High-dose 
MTX therapy for primary CNSL began as high-dose MTX with leucovorin rescue, which 
was first attempted in the late 1970s. It was subsequently combined with WBRT, which 
improved prognosis (median survival: 33–39 months) [5, 6]. 
Rituximab is under vigorous study as a therapeutic option for patients with 
progression or relapse despite initial or second-line therapy with high-dose MTX plus 
WBRT. Rituximab, which was established as a part of R-CHOP therapy, is also expected 
to be a useful therapeutic option for primary CNSL because it enters the cerebrospinal 
fluid after intravenous administration [7]. However, a series of studies reported that 
rituximab monotherapy had limited efficacy, and consequently combination therapy 
had to be considered. Therefore, we have focused on RC, which is approved for the 
treatment of non-Hodgkin’s lymphoma. Cladribine, a purine analogue, inhibits DNA 
synthesis and may induce apoptosis during the proliferative and quiescent phases of 
the cell cycle by depleting nicotinamide adenine dinucleotide and adenosine 
triphosphate. 
We originally introduced RC combination therapy as a salvage treatment for 
refractory aggressive and indolent lymphoma. Subsequently, we found that this 
combination is more effective for CNSL, as shown by the 2 cases described above. 
Delgado et al. [8] reported that cladribine entered the cerebrospinal fluid, and 
Fabianowska-Majewska et al. [9] demonstrated the potent cytocidal effect of cladribine 
on human primary CNSL cells in vitro and discussed potential mechanisms. RC 
combination therapy was administered after high-dose MTX combined with WBRT, a 
conventional therapy for primary CNSL, and complete response was obtained in case 1. 
Furthermore, 1 cycle of RC combination therapy began to exhibit an antitumor effect 
even before the completion of WBRT in case 2. These 2 cases suggest that cladribine 
could cross the blood-brain barrier and reach sufficient cerebrospinal fluid levels to 
have an antitumor effect not only in vitro but also in lymphoma patients. Cladribine has 
potent effects in both proliferating and resting lymphoma cells and has less non-
hematological adverse events such as hair loss, renal dysfunction, hepatic dysfunction, 
interstitial pneumonia, and cardiac toxicity than other anticancer drugs that act during 
the post-G1 phase of the cell cycle. Therefore, cladribine is a useful choice as salvage 
chemotherapy for relapsed and/or refractory lymphomas. However, with the use of  
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cladribine, we have to pay attention to myelosuppression. Secondary MDS arose in case 
1. He was pretreated with 6 cycles of R-THP-COP therapy and high-dose MTX combined 
with WBRT. Therefore, some bone marrow damage might have existed prior to RC 
combination therapy. In addition, considering myelosuppression, the possibility that 6 
cycles of RC combination therapy was excessive is undeniable. The cytotoxic effect 
during the G0/G1 phase of the cell cycle may harm hematopoietic stem cells and may be 
connected with MDS. In case 2, 4 cycles of RC combination therapy was sufficient to 
obtain an antitumor effect, and secondary MDS did not occur. For the above reason, we 
now only administer up to 4 cycles of RC combination therapy.  
The risk of WBRT-related neurotoxicity is unacceptably high. Recent studies have 
focused on either chemotherapy alone or reduced-dose WBRT, but the problem of 
WBRT dose remains unsettled [10]. The 2 cases presented in this paper suggest the 
possibility that the combination of WBRT with RC combination therapy may be able to 
reduce the dose of WBRT, and thus reduce the risk of WBRT-related neurotoxicity. 
In summary, many studies, as well as our own experience, indicate that RC 
combination therapy may be very useful as initial therapy for primary CNSL and as 
salvage therapy for secondary CNSL, pending future evaluations of its efficacy, safety, 
and effect on life expectancy. Our 2 patients with cerebral involvement in malignant 
lymphoma (CD20+) achieved complete response with survival times of 30 months 
(case 1, patient died due to sepsis) and 52 months (case 2, patient is still alive) in 
response to treatment with RC combination therapy. Although RC combination therapy 
is potentially effective against progression or relapse of previously treated CNSL, the 
therapy may need to be stopped if the bone marrow is suppressed and the disease 
progresses, and measures may need to be taken to control susceptibility to infection. 
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Fig. 1. CT images of case 1. Multiple high-density areas surrounded by low-density areas (arrows) 
were observed prior to RC combination therapy (a–d). An effect was apparent after 6 cycles of RC 
combination therapy (e–h). 
 
 
 
Fig. 2. CT (a, b) and MRI (c, d) images of case 2. An effect was apparent (b, d) after 4 cycles of RC 
combination therapy. 
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